Cell secreted proteins for the treatment of myocardial infarction

Abstract

The present invention relates to the use of secreted proteins from mesenchymal stem cells and other cells for the treatment of myocardial infarction. In particular, the invention provides compositions and methods based on secreted proteins from mesenchymal stem cells and the genes encoding them.

The invention claimed is: 
     
       1. A pharmaceutical composition comprising cells, wherein the cells comprise a vector encoding Sparcl1, wherein the cells are mesenchymal stem cells, endothelial progenitor cells, induced pluripotent stem cells, or combinations thereof. 
     
     
       2. A method of treating a vascular disease, a vascular complication, an orthopedic condition, or a degenerative joint disease, in a patient, the method comprising the step of administering to the patient a pharmaceutical composition comprising Sparcl1 in an amount effective to treat a vascular disease, a vascular complication, an orthopedic condition, or a degenerative joint disease. 
     
     
       3. A method of treating a vascular disease, a vascular complication, an orthopedic condition, or a degenerative joint disease, in a patient, the method comprising the step of administering to the patient a pharmaceutically effective amount of a polynucleotide wherein sequence of the polynucleotide encodes Sparcl1, wherein Sparcl1 is expressed in an amount effective to treat a vascular disease, a vascular complication, an orthopedic condition, or a degenerative joint disease. 
     
     
       4. A method of treating a vascular disease or a vascular complication, orthopedic conditions, degenerative joint disease, or effecting wound healing and repair, the method comprising the step of administering to a patient mesenchymal stem cells which express or overexpress Sparcl1. 
     
     
       5. The method as claimed in any of  claims 3  to  4 , wherein the vascular disease or a vascular complication is myocardial infarction, peripheral vascular disease, ischemia, cerebrovascular disease, diabetes mellitus, dyslipidaemia, hypertension, or a combination thereof. 
     
     
       6. A medical device coated with (a) Sparcl1, (b) a vector encoding Sparcl1, (c) mesenchymal stem cells expressing or overexpressing Sparcl1, or (d) a combination thereof, wherein the medical device is a stent, a suture, a dressing, a prosthesis, or combinations thereof. 
     
     
       7. The pharmaceutical composition of  claim 1 , wherein the vector is an adenoviral vector.